Page 58 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

doi: 10.1111/cas.12966 ramucirumab in tyrosine kinase inhibitor-naïve EGFR-
mutant metastatic non-small cell lung cancer (RAMOSE
22. Yang T, Li W, Huang T, Zhou J. Immunotherapy targeting
PD-1/PD-L1 in early-stage triple-negative breast cancer. trial). J Clin Oncol. 2025;43(4):403-411.
J Pers Med. 2023;13(3):526. doi: 10.1200/jco.24.00533
doi: 10.3390/jpm13030526 32. United State Food & Drug. FDA approves osimertinib
with chemotherapy for EGFR-mutated non-small cell
23. Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade
in subprimed CD8 cells induces dysfunctional lung cancer. Available from: https://www.fda.gov/drugs/
PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. resources-information-approved-drugs/fda-approves-
2019;20(9):1231-1243. osimertinib-chemotherapy-egfr-mutated-non-small-cell-
lung-cancer [Last accessed on 2025 Mar 15].
doi: 10.1038/s41590-019-0441-y
33. Lu S, He X, Ni D, Zhang J. Allosteric modulator discovery:
24. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus From serendipity to structure-based design. J Med Chem.
chemotherapy for previously untreated, PD-L1-expressing, 2019;62:6405-6421.
locally advanced or metastatic non-small-cell lung cancer
(KEYNOTE-042): A randomised, open-label, controlled, doi: 10.1021/acs.jmedchem.8b01749
phase 3 trial. Lancet. 2019;393(10183):1819-1830. 34. Cutsem EV, Köhne CH, Hitre E, et al. Cetuximab and
chemotherapy as initial treatment for metastatic colorectal
doi: 10.1016/S0140-6736(18)32409-7
cancer. N Engl J Med. 2009;360(14):1408-1417.
25. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E,
et al. Pembrolizumab plus chemotherapy in metastatic non- doi: 10.1056/NEJMoa0805019
small-cell lung cancer. N Engl J Med. 2018;378(22):2078- 35. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-
2092. FOLFOX4 treatment and RAS mutations in colorectal
cancer. N Engl J Med. 2013;369(11):1023-1034.
doi: 10.1056/NEJMoa1801005
doi: 10.1056/NEJMoa1305275
26. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus
chemotherapy for squamous non-small-cell lung cancer. 36. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus
N Engl J Med. 2018;379(21):2040-2051. guidelines for the management of patients with metastatic
colorectal cancer. Ann Oncol. 2016;27(8):1386-1422.
doi: 10.1056/NEJMoa1810865
doi: 10.1093/annonc/mdw235
27. Jiang Y, Ming C, Hong N, Yuan Y. PD-1 and PD-L1 in
cancer immunotherapy: Clinical implications and future 37. Pietrantonio F, Cremolini C, Petrelli F, et al. First-line
considerations. Hum Vaccines Immunother. 2019;15(5):1111- anti-EGFR monoclonal antibodies in panRAS wild-type
1122. metastatic colorectal cancer: A systematic review and meta-
analysis. Crit Rev Oncol Hematol. 2015;96(1):156-166.
doi: 10.1080/21645515.2019.1571892
doi: 10.1016/j.critrevonc.2015.05.016
28. Ramagopalan S, Gupta A, Arora P, Thorlund K, Ray J, Subbiah V.
Comparative effectiveness of atezolizumab, nivolumab, and 38. Wander S, O’Brien N, Litchfield LM, et al. Targeting CDK4
docetaxel in patients with previously treated non-small cell and 6 in cancer therapy: Emerging preclinical insights
lung cancer. JAMA Netw Open. 2021;4(11):e2134299. related to abemaciclib. Oncologist. 2022;27(10):811-821.
doi: 10.1001/jamanetworkopen.2021.34299 doi: 10.1093/oncolo/oyac138
29. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing 39. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization
guideline for selection of lung cancer patients for EGFR of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-
and ALK tyrosine kinase inhibitors: Guideline from the dependent/independent anti-tumor activities alone/
College of American Pathologists, International association in combination with gemcitabine. Invest New Drugs.
for the study of lung cancer, and association for molecular 2014;32(5):825-837.
pathology. J Thorac Oncol. 2013;8(7):823-859.
doi: 10.1007/s10637-014-0120-7
doi: 10.1097/JTO.0b013e318290868f
40. Chin YM, Shibayama T, Chan HT, et al. Serial circulating
30. Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: tumor DNA monitoring of CDK4/6 inhibitors response in
Molecular mechanisms and emerging treatment options. metastatic breast cancer. Cancer Sci. 2022;113(5):1808-1820.
Cancers. 2023;15(3):841.
doi: 10.1111/cas.15304
doi: 10.3390/cancers15030841
41. O’Keefe K, Desai NV, Tan AR. Practical guidance on
31. Le X, Patel JD, Shum E, et al. A multicenter open-label abemaciclib in combination with adjuvant endocrine
randomized phase II study of osimertinib with and without therapy for treating hormone receptor-positive, human

Volume 8 Issue 3 (2025) 52 doi: 10.36922/ITPS025140018